05.15.18

Singapore-based MediSix Therapeutics, which is developing cellular therapies targeting T-cell leukaemia and lymphoma, announced that it has raised $20 million in Series A financing backed by state investment arm Temasek Holdings.

03.08.18
As an associate professor at The Jackson Laboratory, Kevin Mills zeroed in on the supporting role that the RAD51 protein played in repairing the DNA damage caused by elevated levels of activation-induced cytidine deaminase, or AID.
03.08.18
The rapid growth of cancer cells actually damages them, leading them to rely on internal repair mechanisms. Scientists are finding ways to disrupt these repair features to fight the disease, and their research is leading to a growing crop of startups. Among them: Cambridge, MA-based Cyteir Therapeutics, which has just raised $29 million from Venrock, Celgene, and others.
01.30.18
FIRE1 has raised $50 million to advance remote heart monitoring technology. The device is designed to enable the remote monitoring of heart failure patients and thereby improve outcomes in a group that suffers from persistently high mortality rates.
';